The Use of Androgen Deprivation in Conjunction with Radiation in Localized Prostate Cancer

Omar Mahmoud* and May Abdel-Wahab*

Department of Radiation Oncology, Miller School of Medicine, University of Miami, 1475 NW 12th Ave (D-31), Miami, FL 33136, USA

Abstract: Background: In prostate carcinoma, there is controversy about optimal use of hormonal therapy with external beam radiotherapy: who will benefit, for how long, neo-adjuvant versus concurrent versus adjuvant.

Patients and Methods: Evidence from randomized studies in the light of recent published articles and updates were reviewed in order to address these issues.

Results and Conclusions: From this review it was concluded that the benefit of long-term hormonal therapy in combination with conventional-dose radiotherapy (<74 Gy) in high-risk prostate cancer is evident. For the intermediate risk, the evidence is still weak and studies are awaited to clarify this matter.

Keywords: External beam RT, prostate cancer, androgen suppression duration, androgen suppression timing.

INTRODUCTION

Prostate cancer (PCa), with its lifetime risk of 1:6 men [1], constitutes an important health problem.

Many trials have shown an improved outcome when androgen suppression therapy (AST) is added to radiotherapy (RT) [2-6]. The general trend is to administer 6 months of AST for intermediate-risk patients and 2 to 3 years of treatment for patients with high-risk disease. However, increased recognition of specific side effects related to AST [7, 8] led to new questions regarding the indications for AST and the length of treatment needed.

THE HISTORY AND MECHANISM OF ACTION OF HORMONE THERAPY IN PROSTATE

In his Nobel Lecture 1966, Charles Huggins [9] showed that the hormone-dependent prostate cancer (PCa) cells undergo apoptosis if they are deprived of androgenic stimulation. As a consequence, depletion of circulating testosterone results in shrinkage of the prostate tumors and since then, AST has been used in the treatment of PCa patients.

In androgen-responsive murine adenocarcinoma from a Shinogi SC-115 cell lines, 89 Gy is required for 50% tumor control, however only 60 Gy is required to produce the same result if RT is combined with orchiectomy 1 day before RT. Also when RT preceded AST, the gain was no longer observed, pointing to the potential importance of timing and the advantage of neoadjuvant administration [10].

AST promotes apoptosis and synergistically acts with radiation-induced killing of prostate cancer cells [11]. It also leads to reduction in the size of the prostate with the majority of reduction occurring within the first 3 months [12].

With this rational, clinical studies followed to answer the question of real benefit of combined modality as well as the dose and field issue.

THE COMBINATION OF ADT & RADIOTHERAPY IS BETTER THAN RADIOTHERAPY ALONE

Several Phase III studies have demonstrated that combination of AST and radiotherapy is better than radiotherapy alone [2-6, 13-21].

It is important to note that combining RT and AST was found to be better than AST alone. Widmark et al. [22] reported on 875 locally advanced or high risk patients were randomized to total blockade for 3 months followed by Flutamide continuously versus treating with RT in combination with the same AST regimen. The cumulative incidence of PCa specific mortality at 10 years is 23.9% in endocrine therapy alone versus 11.9% in the combined modality arm, highlighting the importance of local therapy.

EVIDENCE TO SUPPORT AST IN HIGH RISK PCA PATIENTS (TABLE 1)

A recent update of a Swedish trial [19] randomizing 91 patients with locally advanced disease to RT (50 Gy to pelvis and 65 Gy to prostate) with or without orchiectomy was recently published. After up to 19 years follow-up, prostate cancer mortality (57% vs. 36%, p=0.02) was significantly higher for the RT only arm. Subset analysis found that sur-
survival advantage was limited to node positive patients detected by lymphadenectomy.

The EORTC 22863 trial [3] randomized high risk patients (T1-2 WHO grade 3 or T3-4 N0-1) to RT (50 Gy to pelvis and 20 Gy to prostate and seminal vesicles) with or without immediate AST and for 3 years (Goserelin + Cyproterone acetate the first month only). With median follow-up of 66 months, 5-year overall survival was 62% (52-72) and 78% (72-84). In a recent update [23], the author found that the risk of cardiac death was 6% in combined treatment arm versus 4.2% in RT alone arm.

In RTOG 8531, 977 PCA patients with clinical or pathological stage T3 and/or nodal involvement either by radiographic evidence, or after radical prostatectomy, were randomized to either RT alone (with AST at relapse) or RT with AST (started in the last week of radiation and continued indefinitely). RT was 45 Gy to pelvis and 20-25 Gy boost to prostate except in post-prostatectomy patients which formed 15% of patient population. Almost a third of the patients were Gleason 8-10 and almost a third had positive lymph nodes [2].

At 5.6 years median follow-up, 8-year local failure 23% vs. 37% (p<0.0001), distant metastases 27% vs. 37% (p<0.0001), and PSA control 32% vs. 8% (p<0.0001) were in favor of the combined treatment arm [2]. Overall, there was no difference in overall survival or cause-specific survival. However, in subgroup analyses [24], an improvement in overall survival (p=0.036) and cause-specific mortality (p=0.019) was observed in the high risk group (Gleason 8-10).

An update [25] divided patients into three group based on the length of AST (Goserelin) into three groups: less than 1 year, 1 to 5 years, more than 5 years. At median follow-up of 9.6 years and of the 189 analyzable surviving patients, overall survival, disease free survival and fewer distant metastasis were better in the group of more than 5 years AST. Even after adjusting for other variables, AST more than 5 years remained significant for the studied end points. Another report pointing that long-term AST improve survival.

The RTOG 8610 study [13] included 456 men, T3-4 formed 70% and Gleason 8-10 formed 28% of the patient population. They were randomized to RT alone versus AST in addition to RT. AST consisted of 2 months of neoadjuvant AST in addition to RT concurrent with RT or. RT was 44-46 Gy to pelvis, followed by 20-25 Gy boost to prostate. After a median follow-up of 6.7 years, 8-year cause-specific mortality (23% vs. 31%, p=0.05) favoring combined treatment arm. Paradoxically and contrary to RTOG 8531, all endpoints including overall survival (70% vs. 52%, p=0.015) were improved in Gleason 2-6.

Table 1. Trials Comparing Radiotherapy Alone Versus Combined Radiotherapy & Androgen Suppression

<table>
<thead>
<tr>
<th>Trial</th>
<th>Pt Number</th>
<th>Pt Characteristics</th>
<th>RT Fields &amp; Dose</th>
<th>Design</th>
<th>Type of Androgen Suppression</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granfors [19]</td>
<td>91</td>
<td>T1-4 N0-3 WHO 1-3 (intermediate &amp; high risk)</td>
<td>WPI 50Gy &amp; 15Gy PO boost</td>
<td>RT alone vs. Orchiectomy 4 weeks before same RT</td>
<td>Orchiectomy</td>
<td>PCa mortality (57% vs. 36%, p=0.02) in the RT only arm. OAS advantage was limited to N+</td>
</tr>
<tr>
<td>EORTC [3]</td>
<td>415</td>
<td>T3-4 (89%) T1-2 WHO3, All High risk</td>
<td>WPI 50Gy &amp; PO boost 20Gy</td>
<td>RT alone vs. RT + cc &amp; adj AST for 3 years</td>
<td>Goserelin + Cyproterone acetate first month only</td>
<td>5-year OAS was 62% vs. 78%, LC &amp; DFS were all favoring AST containing arm</td>
</tr>
<tr>
<td>RTOG 8531[2]</td>
<td>977</td>
<td>All high risk/T3 or T1-2 N+ or pT3, +SM, +SV</td>
<td>WPI 44-46Gy &amp; 20-25Gy PO Boost, PORT 60-65Gy</td>
<td>RT alone (AST at failure) vs. RT &amp; adj AST for life</td>
<td>Goserelin starting the last week of RT</td>
<td>LC, BC, DM were all better in AST containing arm. OAS advantage in subgroup GS 8-10. Update: longer AST is better</td>
</tr>
<tr>
<td>RTOG 8610 [13]</td>
<td>456</td>
<td>High risk: Bulky T2,T3-4, N+</td>
<td>WPI 44-46Gy &amp; 20-25Gy PO Boost</td>
<td>RT alone vs. RT + Neo for 2 months &amp; cc AST</td>
<td>Goserelin &amp; Flutamide</td>
<td>8-year cause-specific mortality (23% vs. 31%), favoring AST containing arm. OAS advantage in GS2-6</td>
</tr>
<tr>
<td>BWH [18]</td>
<td>206</td>
<td>Intermediate risk 70-85% of Pts: T1b–2b, GS ≥7, PSA 10–40 ng/mL</td>
<td>PO 70 GY</td>
<td>RT alone or RT + adj AST for 6 months</td>
<td>LHRH agonist (Leuprolide or Goserelin) &amp; Flutamide</td>
<td>7.4 years median follow-up showed an increase in all cause mortality in RT alone arm with hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.1-2.9; P=0.01.</td>
</tr>
</tbody>
</table>

RADIOThERAPY DOSE & FIELDS WITH AST

In spite of the evidence favoring the use of AST with RT, it is important to note that most dose escalation studies did not incorporate AST [26-32]. Lab studies hinted toward effectiveness of lower dose of RT with neoadjuvant AST [10]. Thus it remains to be seen if AST can make up for a lower RT dose or make up for a smaller field?

One of the very few studies to combine AST with dose escalation, the MRC RT01 trial [33] compared 64 and 74 Gy to the prostate after 3-6 months of neoadjuvant AST. 843 PCa patients with a median PSA 12.8 ng/ml, Gleason score 8-10 in 13% & 13% had T3 were followed for a median of 63 months. The 5 year biochemical control was 71 versus 61% (p=0.0007) in favor of higher dose.

Two trials addressed the question of whether whole pelvis radiotherapy was needed in patients whose estimated risk of pelvic lymph node involvement was higher than 15%.

The first of these 2 trials: RTOG 9413 a 2×2 randomization study [15] enrolled 1,292 men. Eligible patients had a PSA level of ≤100 ng/ml and an estimated risk of lymph node involvement of >15%. Patients with ct2c–4 and Gleason score ≤6, were eligible even if their calculated risk of lymph node involvement did not reach 15%. They were randomized to either four months of neoadjuvant and concurrent (NCHT) or 4 months of adjuvant (AHT) androgen suppression therapy, and whole pelvic radiotherapy (WPRT) to 50.4 Gy and a boost 19.8 Gy to prostate or prostate-only radiotherapy (PORT) to 70.2Gy. All RT was given at 1.8Gy per fraction. The 4-year progression-free survival was 54% and 47% for the WPRT and PORT arms, respectively (p=0.02). No difference in 4-year progression-free survival was seen between the NCHT and AHT arms (p=0.56).

To analyze the effect of the RT field size and to avoid systemic treatment completion variable, a secondary analysis [34] of two of the four arms was done. Only the NCHT arms were studied, allowing the comparison of WPRT versus PORT. PORT arm was further divided into 2 subgroups the “mini-pelvis group” (>10–11 cm), and the “prostate-only group” (<10–11 cm). As expected and confirming initial publication, improved 4-year progression free survival was significantly associated with larger field size (p=0.024) at the expense of higher acute grade 2 or greater GI toxicities as well as grade 3 late GI toxicities which were more frequent with larger fields (WPRT, “mini-pelvis”, prostate-only: 46.6%, 36.7%, 20.2%, p<0.001). It is important to note that the study used conventional RT techniques rather than IMRT (intensity modulated radiation therapy) which may have adversely affected the toxicity profile.

In a recent update [35] of the RTOG 9413, a median follow-up of 79 months was reached. Interestingly, the initial improvement in progression-free survival seen in the WPRT versus the PORT was lost with longer follow-up (p=0.99). Also, no difference was seen between the NCHT and AHT arms (p=0.59) [35]. On a closer look, WPRT and AHT had a trend for being the least effective arm. When comparing WPRT and AHT versus WPRT and NHT; NHT is significantly better for progression free survival (P=0.014). Also in NHT when comparing WPRT vs. PORT, again WPRT had a trend towards better results with p=0.023. This Pair wise comparison must be viewed with caution as 2×2 factorial designs preclude analysis of significant interaction between arms.

The second trial GETUG-01, a French trial [36], randomized 444 T1b-T3N0 patients, with any PSA, and any Gleason score to WPRT or PORT. Neoadjuvant and concurrent AST for 4–8 months was used in high-risk patients (T3, Gleason score ≥7, or PSA>12). 66-70 Gy was delivered to the prostate. In the trial, almost half of the patients were low risk. No significant difference was seen in 5 year progression free survival between both arms, even for high risk patients.

It must be noted that all AST trials used suboptimal doses in the RT alone arm which was in the range of 66–70Gy. It is not clear whether dose escalation alone would be sufficient to attain equal results as AST and RT.

OPTIMAL TIMING AND DURATION OF AST (TABLE 2)

Lab data [10] and the initial analysis of RTOG 9413 suggest that neoadjuvant AST might be better [15], although this observation did not hold on subsequent analysis [35] or in some other studies [16-17].

In RTOG 9413, which included high risk patients, the duration of either arms NCHT or AHT (4months) was suboptimal to view a benefit as suggested from other trials [14-22, 26-45] that used long-term AST in this patient population. So, a design that incorporates long-term adjuvant AST, with or without neoadjuvant is needed in the high risk category to better elucidate this issue.

Two successive studies from Quebec were conducted to shed light on the issue of timing and duration of AST. The first L-101 randomized 120 T2-3 PCa patients, to RT alone 64 Gy (prostate only) versus RT and neoadjuvant AST (LHRH agonist & Flutamide) for 3 months, versus RT with neoadjuvant, concurrent and adjuvant AST for 10 months [16]. Assessment was by TRUS guided biopsy at 12 and 24 months after the completion of RT. At 12 months, 62%, 30% and 4% of patients had positive biopsies in the RT, RT and neoadjuvant (3 months AST) and RT with 10 months AST groups respectively. Also at 24 months, 65%, 28% and 5% had biopsies that were positive for residual disease in the respective groups above. PSA measurement correlated with biopsy results at 12 months but did not differ between group 2 and 3 at 24 months. These results suggest that AST and RT may be better than RT alone in high risk patients, who constituted about third of the study population. However, the timing of AST needs further clarification as well as the duration in each patient risk category.

That’s why L-200 trial was carried out. The study enrolled 325 patients as opposed to the smaller number (120 patients) enrolled in the L-101. The L-200 study attempted to answer the question of whether 5 versus 10 months of neoadjuvant, concurrent & adjuvant AST with LHRH +Flutamide made a difference in biochemical no evidence of disease (BNED) outcomes. In the L-200 trial, BNED at 4 years was 65% with no difference between 5 and 10 months of AST. Thus, these 2 studies confirm, the lack of a difference between 5 and 10 months of AST and between different timing of AST in this patient population [17].
### Table 2. Trials Comparing Different Timing & Duration of Androgen Suppression Therapy with Radiotherapy

<table>
<thead>
<tr>
<th>Trial</th>
<th>Pts #</th>
<th>Eligibility</th>
<th>RT Fields &amp; Dose</th>
<th>Design</th>
<th>AST</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>EORTC 22961</td>
<td>970</td>
<td>Locally advanced</td>
<td>WPI 50Gy PO, 20Gy</td>
<td>After RT &amp; 6 months of AST, randomization</td>
<td>Triptorelin + Flutamide or Bicalutamide in the first 6 months. Triptorelin for maintenance</td>
<td>5 years overall mortality was 19% versus 15.2% ; more death in short arm</td>
</tr>
<tr>
<td>RTOG 9202</td>
<td>1554</td>
<td>T2c (45%) &amp; T3 (51%) GS 7 (34%) &amp; 8-10 (26%)</td>
<td>45-50Gy WPI &amp; 20-25Gy PO boost</td>
<td>Neo &amp; CC AST 2months with RT then Randomized to observation or 2 years of AST</td>
<td>Flutamide &amp; Goserelin in Neo &amp; CC. Goserelin in long AST arm</td>
<td>5-year DFS 28.1% vs. 46.4% (p&lt;0.0001) &amp; CSS 91.2% vs. 94.6% (p=0.006) in favor of long AST arm. Only in GS 8-10 OAS benefit in long AST arm.</td>
</tr>
<tr>
<td>RTOG 9413</td>
<td>1292</td>
<td>PSA≤100 ng/ml. N+ risk≤15%. T2c-5 GS≥6 even if risk of N+c≤15%</td>
<td>50.4Gy WPI (Large &amp; mini pelvis), 19.8 PO boost vs PO 70.2Gy</td>
<td>2x2 randomization WPI + PO vs PO &amp; neo CC 4 months AST vs 4 months adj AST</td>
<td>Complete blockade with Leuprolide or Goserelin And Flutamide</td>
<td>Initial superiority of WPI &amp; Neo AST lost its significance on PFS. Trends towards superior Neo &amp; WPI over other arms</td>
</tr>
<tr>
<td>TROG 9601</td>
<td>818</td>
<td>80% high risk</td>
<td>66Gy to PO &amp; S.V.</td>
<td>3arms: RT alone, RT with AST 3months (2 months before RT), RT AST 6 (neo 5 months before RT).</td>
<td>LHRH( Leuprolide or Goserelin) and Flutamide</td>
<td>Both AST arms better than RT alone arm in all end points. No difference between 3 &amp; 6 months AST in term of BC or LC.</td>
</tr>
<tr>
<td>L-101 [16]</td>
<td>161</td>
<td>T2-3 PCa pts</td>
<td>64Gy PO</td>
<td>3 arms; RT alone, RT + Neo AST 3months, RT+ Neo Cc, Adj AST 10 months</td>
<td>LHRH agonist &amp; Flutamide</td>
<td>Both AST arm better than RT alone arm in negative biopsy specimen. But Both AST arms didn’t differ at 24 months</td>
</tr>
<tr>
<td>L200 [17]</td>
<td>325</td>
<td>Intermediate &amp; high risk T2-3</td>
<td>64Gy PO</td>
<td>RT + Neo cc Adj 5 months vs 10 months</td>
<td>LHRH agonist &amp; Flutamide</td>
<td>4 years BC was 65% with no difference between 5 &amp; 10 months of AST</td>
</tr>
<tr>
<td>CUOG [20]</td>
<td>378</td>
<td>Intermediate (43%) &amp; high risk T2c-T4</td>
<td>66Gy PO, if N+ risk≥10% WPI 45 Gy</td>
<td>Neo AST 3 months versus 8 months with RT</td>
<td>Goserelin &amp; Flutamide</td>
<td>DFS at 5 years was improved for the high-risk patients in the 8-month arm (71% vs. 42%, p = 0.01). Otherwise, no difference in all end points in other pts between 3 &amp; 8 months neo AST</td>
</tr>
</tbody>
</table>


One of the possible explanations was that the percentage of high risk patients, who are known to benefit from longer AST, was small. This explanation is further supported by data showing, the lack of additional benefit to longer AST in the intermediate risk population. Such as that from the Canadian study [20] which confirmed that longer versus shorter neoadjuvant AST is no benefit in intermediate risk population.

378 PCa men with T1c–4, any PSA, and any Gleason score were randomized in the Canadian trial [20] to either 3 or 8 months of neoadjuvant AST (Goserelin and Flutamide) prior to radiotherapy (66–67 Gy to the prostate). Patients with an estimated nodal involvement of >10–15% received whole-pelvic radiotherapy (45–46 Gy). Low risk population constituted 26% while the intermediate risk group constituted 43% of the study population. Median follow-up was 44 months. No significant difference was noted in any of the end points [20]. An update published in 2009 with 6.6 years median follow-up [37], again showed no difference in all end points with the exception of high risk patients that benefited from longer AST with an improved disease-free survival rate at 5 years compared to the 8-month arm (71% vs. 42%, p = 0.01).

### OPTIMAL DURATION OF NEOADJUVANT AST

From Australia [6], TROG 9601 randomized 818 PCa patients to one of three arms: RT alone, RT with 3 months AST (LHRH agonist + Flutamide) (started 2 months before radiotherapy), or RT with 6 months of AST (started 5 months before radiotherapy). Radiotherapy was delivered the prostate and seminal vesicles to a total dose of 66 Gy in 33 fractions. More than 80% of patients qualified as high risk.
At a median follow-up of 5.9 years, 3 months of AST significantly improved biochemical control (HR 0.70, p=0.002), and disease-free survival (HR 0.65, p=0.0001) when compared to RT alone. However, a longer AST duration of 6 months not only significantly improved biochemical control (HR 0.58, p=0.0001) and disease-free survival (HR 0.56, p<0.0001), but also distant failure (HR 0.67, p=0.046), and prostate cancer specific survival (HR 0.56, p=0.04) when compared to RT. On the other hand, no difference in local control or biochemical free survival was noticed between the 3 and 6 month groups. Subgroup analysis for the benefit of AST in intermediate risk showed no significant DFS with HR= 0.8 in favor of AST but the CI was wide (0.45-1.42).

The Canadian [20] and Australian [6] trials are inconsistent in patient population and in results, however, they suggest that longer AST is beneficial in high risk patients and of minimal benefit for intermediate risk patients.

**AST IN INTERMEDIATE RISK PATIENTS**

Data regarding AST are limited in the intermediate risk population. Furthermore, the optimum duration, and need for AST are controversial in the setting of dose escalation.

D’Amico trial [18] randomized 206 patients with mostly (70-85%) intermediate risk prostate cancer to radiotherapy alone or radiotherapy with 6 months of androgen suppression therapy (AST) (LHRH agonist and Flutamide, both for 6 months). The study population had a median PSA of 11 ng/ml, a PSA velocity more than 2ng/ml/year; clinical T1 (48%) and T2 (52%) disease and a range of Gleason scores from <7 (27%) and 7 (58%), to 8–10 (15%). Conformal radiotherapy was used to treat the prostate only delivering 70Gy over 35 fractions. At a median follow-up of 4.52 years, the combined arm did better with 5-year overall survival (88% vs. 78%, p=0.04), cause-specific survival (100% vs. 94%, p=0.02), and PSA control (79% vs. 55%, p<0.001). The update [5] of this trial after 7.4 years median follow-up showed an increase in all cause mortality in radiotherapy alone arm with hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.1-2.9; P=0.01). Assessment of co-morbidities and their interaction with the results was added to this update: In the 157 men with no or minimal co morbidity scores, treatment with RT and AST compared with RT was associated with a significantly higher survival; HR, 4.2; 95% CI, 2.1-8.5; P=0.001), with Kaplan-Meier 8-year survival estimates of 90% (95% CI, 79%-95%) and 64% (95% CI, 49%-75%), respectively.

The take home message from the update is that, men with little co-morbidity, intermediate risk PCa and PSA velocity more than 2ng/ml/year benefit from abbreviated course of androgen suppression.

Results of the RTOG 9910 and RTOG 9406 studies, which included a majority of patients in the low or intermediate risk group, are awaited to shed light on the need for and the duration of AST in this particular population.

**LONGER VERSUS SHORTER ADJUVANT AST IN HIGH RISK PATIENTS**

The prolonged use of AST, especially in older patients, may lead to several complications, including decline in bone density, osteoporosis, fractures [38] decrease in muscle strength [39, 40] mental changes [41] and metabolic syn-}

drome and cardiac toxicity [42] with a significant impact in patients’ quality of life [43].

This concern led to a combined analysis of the 3 studies led by D’Amico [18], Denham [6] and Bolla [3] to compare short versus long-term AST. After adjusting for known prognostic factors in high risk patients, long-term AST did not result in significant prolongation of survival in older men [44].

More interestingly, the long-awaited EORTC 22961 was recently published [45] to answer the question of long versus short-term AST. In this context, 970 locally advanced PCa patients were randomized after Conformal RT (50 Gy to pelvis & 20 Gy to prostate and seminal vesicles) and 6 months AST (LHRH agonist Triptorelin and anti-androgen Flutamide or Bicalutamide) to observation versus continued AST with Triptorelin for 2.5 years. After median follow-up of 6.6 years, the 5 years overall mortality was 19% versus 15.2% and hazard ratio was 1.42 in short versus long-term AST with p=0.6 for non inferiority of the short, which confirms that shorter AST provides inferior overall survival results. Importantly, no difference in death from other causes was noted between the 2 arms, including fatal cardiac myocardial infarction.

1,554 men with high risk PCa, T2c (45%) & T3 (51%), Gleason score 7 in 34% & 8-10 in 26% were randomized in RTOG 9202 after 2 months of neoadjuvant and concurrent hormones with radiotherapy to either observation or 2 years of adjuvant hormones [14]. RT was 45-50 Gy to pelvis and 20-25 Gy to prostate boost. At 5.8 years median follow-up, the 5-year disease-free survival was 28.1% vs. 46.4% (p<0.0001) and cause-specific survival was 91.2% vs. 94.6% (p=0.006), in favor of the 2 year adjuvant hormone arm. Overall survival, was significantly improved in the adjuvant hormones arm, but only in Gleason score 8-10 subset. The update after 10 years [46] showed again that in the high risk group with Gleason score 8-10, long-term adjuvant AST improve survival 31.9% versus 45.1% (P =0.0061).

**CONCLUSION AND FUTURE PERSPECTIVES**

AST has an important role in the treatment of high risk prostate cancer patients in the setting of definitive radiation therapy with conventional doses. Some benefits can also be seen in select intermediate risk patients. Less information is available regarding the use of AST in the dose-escalation setting.

The future brings new perspectives and new exciting discoveries. Identification of high risk patients based on the molecular background rather that actual risk stratification will further refine treatment decisions regarding who will benefit from AST and how to prevent relapse [47]. Advanced imaging techniques to help detect early lymph node spread may have a role in future recommendations for AST. New markers will better segment completely eradicated PCa from those who still have disease and who will benefit more from other form of treatment.

Chemotherapy and new targeted therapies may eventually add to the management of high risk patients.

Tumor vaccine as well as new anti androgen and other may prove to be more efficient.
REFERENCES


The Use of Androgen Deprivation in Conjunction with Radiation


Received: August 29, 2009 Revised: December 19, 2009 Accepted: December 19, 2009

© Mahmoud and Abdel-Wahab; Licensee Bentham Open.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.